D. Boral Capital Reiterates “Buy” Rating for Anavex Life Sciences (NASDAQ:AVXL)

Anavex Life Sciences (NASDAQ:AVXL)‘s stock had its “buy” rating reissued by analysts at D. Boral Capital in a report released on Monday,Benzinga reports. They currently have a $46.00 target price on the biotechnology company’s stock. D. Boral Capital’s price objective would indicate a potential upside of 409.41% from the stock’s current price.

Separately, HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Anavex Life Sciences in a report on Monday, November 4th.

Anavex Life Sciences Stock Performance

Shares of AVXL stock opened at $9.03 on Monday. Anavex Life Sciences has a fifty-two week low of $3.25 and a fifty-two week high of $10.45. The firm has a market cap of $765.71 million, a P/E ratio of -18.06 and a beta of 0.60. The business’s 50 day moving average price is $6.46 and its 200-day moving average price is $5.58.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC bought a new position in Anavex Life Sciences in the second quarter worth $57,000. Orion Capital Management LLC increased its stake in shares of Anavex Life Sciences by 666.7% in the 3rd quarter. Orion Capital Management LLC now owns 11,500 shares of the biotechnology company’s stock worth $65,000 after acquiring an additional 10,000 shares in the last quarter. PVG Asset Management Corp purchased a new position in Anavex Life Sciences during the 3rd quarter valued at about $74,000. Atria Investments Inc purchased a new position in Anavex Life Sciences during the 3rd quarter valued at about $76,000. Finally, Fiduciary Alliance LLC boosted its stake in Anavex Life Sciences by 45.2% during the second quarter. Fiduciary Alliance LLC now owns 19,275 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 6,000 shares in the last quarter. Hedge funds and other institutional investors own 31.55% of the company’s stock.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.